Literature DB >> 15022184

Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.

Peter Haussermann1, Stefanie Marczoch, Christiane Klinger, Michael Landgrebe, Bastian Conrad, Andres Ceballos-Baumann.   

Abstract

We followed the course in 100 consecutive patients with cervical dystonia (CD) after they were initially treated with botulinum toxin (BTX) in the form of Dysport 10 to 12 years ago. A total of 4 patients had died, and 6 were lost to follow-up. Of the remaining 90 patients, 57 (63%) were still treated with BTX. In the patients treated at one centre over the whole period with Dysport, mean dose used during each treatment session was 833 (SD +/- 339) units Dysport with a cumulative dose of 20,943 (SD +/- 9462) units Dysport over a mean of 26.8 (SD +/- 8.6) treatment cycles. Secondary nonresponse was detected in 3 of the 90 patients. During follow-up, 12 patients developed blepharospasm, 13 oromandibular dystonia, and 17 patients writer's cramp. We conclude that BTX remains effective and safe for approximately 60% of CD patients for more than 10 years. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15022184     DOI: 10.1002/mds.10659

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  27 in total

1.  Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia.

Authors:  Andre C Felicio; Clecio Godeiro-Junior; Patricia de Carvalho Aguiar; Vanderci Borges; Sonia M A Silva; Henrique B Ferraz
Journal:  Neurol Sci       Date:  2009-05-26       Impact factor: 3.307

2.  Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia.

Authors:  A R Bentivoglio; E Di Stasio; D Mulas; M L Cerbarano; T Ialongo; A Laurienzo; Martina Petracca
Journal:  Neurotox Res       Date:  2017-05-06       Impact factor: 3.911

3.  [Botulinum toxin therapy for spasmodic torticollis: medical and non-medical adjunct treatment].

Authors:  B Leplow; M Böttcher; R Schönfeld
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

4.  Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia.

Authors:  Joaquim J Ferreira; Roongroj Bhidayasiri; Carlo Colosimo; Maria Jose Marti; Benjamin Zakine; Pascal Maisonobe
Journal:  Funct Neurol       Date:  2012 Oct-Dec

Review 5.  [Modern non-cosmetic treatment with botulinum toxins].

Authors:  A Straube
Journal:  Internist (Berl)       Date:  2017-12       Impact factor: 0.743

6.  Efficacy and Safety of Long-Term Therapy with Type A Botulinum Toxin in Patients with Blepharospasm.

Authors:  Francisco Vivancos-Matellano; Ana Rodríguez-Sanz; Yolanda Herrero-Infante; Javier Mascías-Cadavid
Journal:  Neuroophthalmology       Date:  2018-11-26

7.  Clinical Characteristics and Response to Long-Term Botulinum Toxin Type A Therapy in Patients with Cervical Dystonia at a Neurology Clinic.

Authors:  Aysu Şen; Aysun Soysal; Baki Arpaci
Journal:  Noro Psikiyatr Ars       Date:  2014-12-01       Impact factor: 1.339

8.  Experience with long-term treatment with albumin-supplemented botulinum toxin type A.

Authors:  Bahram Mohammadi; Katja Kollewe; Maresa Wegener; Hans Bigalke; Reinhard Dengler
Journal:  J Neural Transm (Vienna)       Date:  2009-03-25       Impact factor: 3.575

Review 9.  Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?

Authors:  H A Jinnah; Cynthia L Comella; Joel Perlmutter; Codrin Lungu; Mark Hallett
Journal:  Toxicon       Date:  2017-09-06       Impact factor: 3.033

10.  Botulinum toxin type A in the treatment of patients with cervical dystonia.

Authors:  Allison Brashear
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.